Tetrandrine - CBA Pharma

Drug Profile

Tetrandrine - CBA Pharma

Alternative Names: CBT-1; NSC-77037

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CBA Pharma
  • Developer CBA Pharma; National Cancer Institute (USA)
  • Class Alkaloids; Antiarrhythmics; Antihypertensives; Antimalarials; Antineoplastics; Benzylisoquinolines; Small molecules
  • Mechanism of Action Calcium channel antagonists; Immunosuppressants; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Cancer
  • Phase III Non-small cell lung cancer
  • Phase II Acute myeloid leukaemia; Breast cancer; Cervical cancer; Gastrointestinal cancer; Head and neck cancer; Lung cancer; Multiple myeloma; Ovarian cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours
  • Phase I Sarcoma

Most Recent Events

  • 29 Mar 2018 Phase-I clinical trials in Sarcoma (Adjunctive treatment, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (PO) (NCT03002805)
  • 08 Dec 2017 Chemical structure information added
  • 29 Dec 2016 CBA Pharma plans a phase I trial for Sarcoma (Adjunctive treatment, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (PO) (NCT03002805)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top